title: Systemic treatment of vitreous inflammation.
abstract: Non infectious vitreous inflammation is often vision threatening and can be associated with potentially life-threatening systemic conditions. Treatment is often challenging as it involves systemic medications that can be associated with adverse effects. The classes of drugs are ever expanding and include corticosteroids, antimetabolites, alkylating agents, T-cell and calcineurin agents, biologic agents, and interferons. Each class of systemic therapy for non-infectious vitreous inflammation is reviewed. We discuss the mechanisms of action, usual clinical dosages, the specific conditions that are treated, the adverse effects, and usual course of treatment for each class of therapy.
authors.affiliation: Retina Division, Department of Ophthalmology, Wexner Medical Center at The Ohio State University, 915 Olentangy River Road, Suite 5000, Columbus, OH 43212, USA. jbchristo@hotmail.com
authors.forename: John B
authors.initials: JB
authors.lastname: Christoforidis
authors.forename: Susie
authors.initials: S
authors.lastname: Chang
authors.forename: Angela
authors.initials: A
authors.lastname: Jiang
authors.forename: Jillian
authors.initials: J
authors.lastname: Wang
authors.forename: Colleen M
authors.initials: CM
authors.lastname: Cebulla
mesh_terms: D000305:Adrenal Cortex Hormones / Q000627:therapeutic use; D000963:Antimetabolites / Q000627:therapeutic use; D001688:Biological Products / Q000627:therapeutic use; D006801:Humans; D007249:Inflammation / Q000188:drug therapy*; D007372:Interferons / Q000627:therapeutic use; D014822:Vitreous Body / Q000187:drug effects / Q000473:pathology*
chemical_list: D000305:Adrenal Cortex Hormones; D000963:Antimetabolites; D001688:Biological Products; D007372:Interferons